EHS
EHS

Assembly Biosciences initiates phase 2a trial for HBV core inhibitor

Assembly Bioscience announced the initiation of two randomized control phase 2a trials for ABI-H0731, the company’s lead hepatitis B core inhibitor, according to a press release.
ABI-H0731 previously demonstrated potent antiviral activity in a phase 1b trial, the results of which were presented at the International Liver Congress 2018 in Paris.
“These studies will provide data on the potential of ABI-H0731 to increase cure rates by suppressing viral replication to a greater degree than is currently achieved with standard nucleos(t)ide therapy alone,” Uri Lopatin, MD, chief
EHS
Back to top button